Merck's CAPVAXIVE gets FDA approval for at-risk children
The vaccine is indicated for children aged 2-17 with increased pneumococcal disease risk, adding serotype coverage.
See the latest news and media coverage for Merck. We track all announcements, press releases, and industry mentions in real time, all in one place.
Research-intensive biopharmaceutical company
merck.comLast updated
In short: Merck acquired Targan to bolster its animal-health unit and reported positive Phase 3 results for HIV and cancer treatments, despite some setbacks.
The vaccine is indicated for children aged 2-17 with increased pneumococcal disease risk, adding serotype coverage.
Approvals add WELIREG combinations for adjuvant treatment of intermediate‑high or high‑risk ccRCC after nephrectomy. Based on Phase 3 LITESPARK‑022 showing 28% reduced risk of recurrence, metastasis or death.
The acquisition includes TARGAN's biodevice technology for poultry performance improvement.
The islatravir/lenacapavir regimen met efficacy endpoints with comparable safety in two studies.
Drugmaker Merck said on Thursday the U.S. health regulator has approved an expanded use of its pneumococcal vaccine for children and teenagers who face a...
Siemens Fonds Invest GmbH reduced its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 8.8% in the 4th quarter, according to its...
A Danish physician who led Merck-sponsored Gardasil clinical trials and later ran a government clinic for injured patients concluded the HPV vaccine was the probable...
Merck (NYSE:MRK) announced a multi target AI drug discovery collaboration with Protillion Biosciences, focused on high throughput protein engineering for new therapeutics. The agreement includes...
Track Merck and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Merck and other trending companies.